These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1182 related items for PubMed ID: 17583392

  • 21. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae--Massachusetts, 2001-2006.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2007 Oct 19; 56(41):1077-80. PubMed ID: 17947966
    [Abstract] [Full Text] [Related]

  • 22. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease.
    Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, Santosham M, O'Brien KL.
    Clin Infect Dis; 2010 May 01; 50(9):1238-46. PubMed ID: 20367225
    [Abstract] [Full Text] [Related]

  • 23. The future of pneumococcal disease prevention.
    Rodgers GL, Klugman KP.
    Vaccine; 2011 Sep 14; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [Abstract] [Full Text] [Related]

  • 24. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006.
    Motlova J, Benes C, Kriz P.
    Epidemiol Infect; 2009 Apr 14; 137(4):562-9. PubMed ID: 18796171
    [Abstract] [Full Text] [Related]

  • 25. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.
    Dagan R.
    Clin Microbiol Infect; 2009 Apr 14; 15 Suppl 3():16-20. PubMed ID: 19366365
    [Abstract] [Full Text] [Related]

  • 26. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F, Horcajada I, Cañas AM, Alamo I, Bordes A, González A, Santana M, Lafarga B.
    Enferm Infecc Microbiol Clin; 2009 Jan 14; 27(1):14-21. PubMed ID: 19217998
    [Abstract] [Full Text] [Related]

  • 27. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine.
    McEllistrem MC, Adams JM, Patel K, Mendelsohn AB, Kaplan SL, Bradley JS, Schutze GE, Kim KS, Mason EO, Wald ER.
    Clin Infect Dis; 2005 Jun 15; 40(12):1738-44. PubMed ID: 15909260
    [Abstract] [Full Text] [Related]

  • 28. Invasive pneumococcal infections among vaccinated children in the United States.
    Park SY, Van Beneden CA, Pilishvili T, Martin M, Facklam RR, Whitney CG, Active Bacterial Core surveillance team.
    J Pediatr; 2010 Mar 15; 156(3):478-483.e2. PubMed ID: 19962156
    [Abstract] [Full Text] [Related]

  • 29. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 30. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations.
    Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF.
    Vaccine; 2009 Jul 23; 27(34):4694-703. PubMed ID: 19520197
    [Abstract] [Full Text] [Related]

  • 31. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).
    Isaacman DJ, Fletcher MA, Fritzell B, Ciuryla V, Schranz J.
    Vaccine; 2007 Mar 22; 25(13):2420-7. PubMed ID: 17049677
    [Abstract] [Full Text] [Related]

  • 32. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.
    Hsu KK, Shea KM, Stevenson AE, Pelton SI, Massachusetts Department of Public Health.
    Pediatr Infect Dis J; 2010 Apr 22; 29(4):289-93. PubMed ID: 19935447
    [Abstract] [Full Text] [Related]

  • 33. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
    Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR, Active Bacterial Core Surveillance/Emerging Infections Program Network.
    J Infect Dis; 2010 Jan 01; 201(1):32-41. PubMed ID: 19947881
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF, Løvoll O, Aaberge IS, Caugant DA, Høiby EA, Bakke H, Bergsaker MR.
    Vaccine; 2008 Jun 19; 26(26):3277-81. PubMed ID: 18456376
    [Abstract] [Full Text] [Related]

  • 35. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine.
    Jacobs MR, Good CE, Bajaksouzian S, Windau AR.
    Clin Infect Dis; 2008 Dec 01; 47(11):1388-95. PubMed ID: 18959493
    [Abstract] [Full Text] [Related]

  • 36. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain.
    Benito-Fernández J, Raso SM, Pocheville-Gurutzeta I, SánchezEtxaniz J, Azcunaga-Santibañez B, Capapé-Zache S.
    Pediatr Infect Dis J; 2007 Aug 01; 26(8):667-71. PubMed ID: 17848875
    [Abstract] [Full Text] [Related]

  • 37. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.
    Miller E, Andrews NJ, Waight PA, Slack MP, George RC.
    Lancet Infect Dis; 2011 Oct 01; 11(10):760-8. PubMed ID: 21621466
    [Abstract] [Full Text] [Related]

  • 38. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children.
    Park SY, Moore MR, Bruden DL, Hyde TB, Reasonover AL, Harker-Jones M, Rudolph KM, Hurlburt DA, Parks DJ, Parkinson AJ, Schuchat A, Hennessy TW.
    Pediatr Infect Dis J; 2008 Apr 01; 27(4):335-40. PubMed ID: 18316986
    [Abstract] [Full Text] [Related]

  • 39. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL, Michaels MG, Green M, Mazariegos GV, Webber SA, Lawrence KS, Iurlano K, Greenberg DP.
    Pediatrics; 2005 Jul 01; 116(1):160-7. PubMed ID: 15995047
    [Abstract] [Full Text] [Related]

  • 40. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.
    Pletz MW, Maus U, Krug N, Welte T, Lode H.
    Int J Antimicrob Agents; 2008 Sep 01; 32(3):199-206. PubMed ID: 18378430
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.